Table Graph
      published meta-analysis   sensitivity analysis   studies

colchicine in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsBrunetti, 2020 0.20 [0.05; 0.80] 0.20[0.05; 0.80]Brunetti, 202010%66NAnot evaluable deathsdetailed resultsBrunetti, 2020 0.20 [0.05; 0.80] COLCHIVID, 2021 0.69 [0.20; 2.40] 0.39[0.11; 1.30]Brunetti, 2020, COLCHIVID, 2021241%192NAnot evaluable clinical improvement (28-day)detailed resultsBrunetti, 2020 3.50 [1.19; 10.29] 3.50[1.19; 10.29]Brunetti, 202010%66NAnot evaluable hospital dischargedetailed resultsBrunetti, 2020 5.00 [1.25; 20.04] COLCHIVID, 2021 1.13 [0.76; 1.67] 2.04[0.49; 8.46]Brunetti, 2020, COLCHIVID, 2021276%192NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-06-15 20:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 560,1102 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons